CN112379102A - Rhodium nanoparticle-ferritin polyclonal antibody compound and ferritin rapid detection test strip - Google Patents

Rhodium nanoparticle-ferritin polyclonal antibody compound and ferritin rapid detection test strip Download PDF

Info

Publication number
CN112379102A
CN112379102A CN202011184144.9A CN202011184144A CN112379102A CN 112379102 A CN112379102 A CN 112379102A CN 202011184144 A CN202011184144 A CN 202011184144A CN 112379102 A CN112379102 A CN 112379102A
Authority
CN
China
Prior art keywords
ferritin
polyclonal antibody
rhodium
nanoparticle
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011184144.9A
Other languages
Chinese (zh)
Inventor
赵肃清
何绮怡
杨慧怡
范冠浪
金晶
陈憬宏
崔锡平
李清兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong University of Technology
Original Assignee
Guangdong University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong University of Technology filed Critical Guangdong University of Technology
Priority to CN202011184144.9A priority Critical patent/CN112379102A/en
Publication of CN112379102A publication Critical patent/CN112379102A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to the technical field of immunodetection, in particular to a rhodium nanoparticle-ferritin polyclonal antibody compound and a ferritin rapid detection test strip. The invention discloses a rhodium nanoparticle-ferritin polyclonal antibody compound, wherein the rhodium nanoparticle in the compound has horseradish peroxidase-like activity and can replace the tracing effect of colloidal gold on the traditional immune test strip. The compound is applied to a test strip, is combined with a ferritin polyclonal antibody to establish a double-antibody sandwich type immunoassay test strip, has high specificity to ferritin, good sensitivity and low detection limit, and can quickly and accurately detect the ferritin in serum.

Description

Rhodium nanoparticle-ferritin polyclonal antibody compound and ferritin rapid detection test strip
Technical Field
The invention relates to the technical field of immunodetection, in particular to a rhodium nanoparticle-ferritin polyclonal antibody compound and a ferritin rapid detection test strip.
Background
Ferritin is a metalloprotein ubiquitous in the body, having a nanoscale hydrated iron oxide core and a protein shell with a cage-like structure. Ferritin is widely found in liver and spleen tissues. Excessive iron deposition in the liver can lead to damage to hepatocytes. Typically, serum ferritin levels are maintained within a relatively stable range, whereas WHO dictates normal concentrations of ferritin in between 30-300ng/mL and 15-200ng/mL for men and women, respectively. Abnormal elevation of serum ferritin may reflect a variety of diseases such as hepatitis, cirrhosis, liver cancer, lung cancer, leukemia, etc. In addition, a reduction in serum ferritin can lead to anemia and malnutrition. Therefore, the detection of the ferritin in the serum has certain clinical guidance value. In the past decades, several methods for assaying ferritin have been established, such as electrochemical immunosensors, radioimmunoassays, and inductively coupled plasma mass spectrometry (ICP-MS). Although these methods are relatively sensitive and have excellent selectivity, these instruments are expensive, complicated to operate, require special expertise and highly trained operators.
The immunochromatography method can effectively improve the detection efficiency and accuracy of the content of the serum ferritin. At present, the materials for marking the immunochromatographic test strip are mainly colloidal gold nanoparticles, the colloidal gold is red, and the marker is relatively stable, so that the immunochromatographic test strip is widely applied to the immunochromatographic test strip. However, in practical application, it can be found that colloidal gold is easy to coagulate and discolor in a high-salt environment, so that a dead gold phenomenon is generated, and the detection effect is influenced.
Disclosure of Invention
The invention provides a rhodium nanoparticle-ferritin polyclonal antibody compound and a ferritin rapid detection test strip, and solves the problem that colloidal gold in the existing immunochromatographic test strip is easy to be coagulated and discolored in a high-salt environment, so that the detection effect is influenced.
The specific technical scheme is as follows:
the invention provides a rhodium nanoparticle-ferritin polyclonal antibody compound, which comprises the following components in percentage by weight: rhodium nanoparticles and ferritin polyclonal antibodies coupled to the rhodium nanoparticles.
The rhodium nanoparticles are stable, high-temperature resistant and pH resistant in a high-salt environment, the using efficiency of the immunochromatography method can be effectively improved, the rhodium nanoparticles used in the method have horseradish peroxidase-like activity, and a chromogenic signal can be improved through a catalytic reaction, so that the amplification of a detection signal is realized.
In the invention, the rabbit anti-human ferritin polyclonal antibody is obtained by immunizing animals with human ferritin, taking blood and centrifuging.
In the invention, the ferritin polyclonal antibody is a rabbit anti-human ferritin polyclonal antibody.
In the invention, the mass ratio of the rhodium nanoparticles to the ferritin polyclonal antibody is 800: (5-25), preferably 800: 10.
The invention also provides a preparation method of the rhodium nanoparticle-ferritin polyclonal antibody compound, which comprises the following steps:
step 1: reacting RhCl3Mixing the aqueous solution, hexadecyl trimethyl ammonium chloride and ascorbic acid, and reacting to obtain rhodium nanoparticles;
step 2: and mixing the aqueous solution of the rhodium nanoparticles, the aqueous alkali solution and the ferritin polyclonal antibody, reacting, and then adding a confining liquid for confining to obtain the rhodium nanoparticle-ferritin polyclonal antibody compound.
In step 1 of the present invention, RhCl3The dosage ratio of the hexadecyl trimethyl ammonium chloride to the ascorbic acid is (3-20) mg: (50-200) mg: (50-200) mL, preferably 10 mg: 10 mg: 1 mL;
the RhCl3The concentration of the aqueous solution is 0.3-5 mg/mL, preferably 2 mg/mL.
In step 2 of the invention, the alkali solution is preferably potassium carbonate solution, and the blocking solution is preferably bovine serum albumin;
the concentration of the alkali solution is 0.2M, the concentration of the ferritin polyclonal antibody is 1mg/mL, the concentration of the confining liquid is 0.1mg/mL, and the concentration of the aqueous solution of the rhodium nanoparticles is 1.5-1.6 mg/mL;
the volume ratio of the aqueous solution of the rhodium nanoparticles, the alkali solution, the ferritin polyclonal antibody and the blocking solution is (1000-4000): (0-8): (1-10): 100.
the invention also provides the application of the rhodium nanoparticle-ferritin polyclonal antibody compound or the rhodium nanoparticle-ferritin polyclonal antibody compound prepared by the preparation method in ferritin detection.
The invention also provides a ferritin rapid detection test strip, which comprises: a base plate;
the bottom plate is sequentially provided with a sample pad, a combination pad, a nitrocellulose membrane and absorbent paper;
the combination pad is coated with the rhodium nanoparticle-ferritin polyclonal antibody compound or the rhodium nanoparticle-ferritin polyclonal antibody compound prepared by the preparation method, and the nitrocellulose membrane is sequentially scribed with a detection line of a ferritin monoclonal antibody and a quality control line of a goat anti-rabbit IgG antibody.
In the invention, the ferritin monoclonal antibody is a mouse anti-human ferritin monoclonal antibody.
In the invention, the concentration of the rhodium nanoparticle-ferritin polyclonal antibody compound is 5-30mg/mL, preferably 20mg/mL, and the spraying amount is 7.5-10.0 muL/cm, preferably 7.5 muL/cm or 8.5 muL/cm;
the concentration of the ferritin monoclonal antibody is 0.1-1.0mg/mL, preferably 0.2mg/mL, and the spraying amount is 1 muL/cm;
the concentration of the goat anti-rabbit IgG antibody is 0.1-1.0mg/mL, preferably 1.0mg/mL, and the spraying amount is 1 muL/cm.
In the invention, the distance between the quality control line and the detection line is 5 mm.
In the invention, the test strip further comprises: 3,3',5,5' -tetramethylbenzidine solution (TMB) and hydrogen peroxide solution. After the test of the serum to be detected is finished, preferably, the serum to be detected is dripped into the sample pad for 15min, the mixed solution is dripped into the detection line, the rhodium nanoparticles can catalyze TMB into oxidation type TMB, the oxidation type TMB is blue, the color of the rhodium nanoparticles is overlapped, the color development signal is improved, and the color development signal is used as an amplification signal for ferritin detection.
In the present invention, the amount of the mixed solution is 2 μ L, wherein the concentration of the TMB solution is 0.1M, the concentration of the hydrogen peroxide solution is 0.1M, and the molar ratio of TMB to hydrogen peroxide is 1: 1.
the invention also provides a method for rapidly detecting ferritin in serum, which comprises the following steps:
and (3) dropping serum to be detected on the sample pad in the ferritin rapid detection test strip, if the detection line and the quality control line are both colored, the ferritin in serum to be detected is detected, and if the detection line is not colored, and the quality control line is colored, the ferritin is not contained in the serum to be detected.
In the invention, the dosage of the serum to be detected is 80-150 mu L, preferably 100 mu L
In the invention, the principle of the ferritin rapid detection test strip is as follows:
after the serum to be detected is dripped into the test strip sample pad, the sample solution diffuses to the other end due to the capillary action of the nitrocellulose membrane carrier. During the movement, corresponding antigen-antibody reaction occurs, and the reaction is shown by the color of the rhodium nano-particles. If the sample solution to be detected contains ferritin, the ferritin firstly reacts with the rhodium nanoparticle-ferritin polyclonal antibody on the binding pad. When the rhodium nanoparticles diffuse to the detection line along with the sample solution, the ferritin monoclonal antibody is specifically combined with ferritin again to display a detection trace, and the goat anti-rabbit IgG antibody can be combined with the antibody again to color the quality control line, preferably, a mixed solution of TMB and hydrogen peroxide is dripped on the detection line to serve as an amplification signal of the ferritin on the detection line; on the contrary, when no ferritin exists in serum to be detected, the rhodium nanoparticle-ferritin polyclonal antibody and the ferritin monoclonal antibody do not have antigen-antibody reaction, the detection line does not develop color, and the goat anti-rabbit IgG antibody in the quality control area can be combined with the antibody and only the quality control line develops color; if the quality control line on the cellulose membrane and the detection line do not develop color, the test strip is invalid.
The invention adopts a double-resistance sandwich type immunoassay method which has high specificity and good sensitivity.
According to the technical scheme, the invention has the following advantages:
the invention provides a rhodium nanoparticle-ferritin polyclonal antibody compound, wherein the rhodium nanoparticle in the compound has horseradish peroxidase-like activity and can replace the tracing effect of colloidal gold on the traditional immune test strip. The compound is applied to a test strip and combined with a ferritin polyclonal antibody, a double-antibody sandwich type immunoassay test strip is proposed, the test strip has high specificity to ferritin, good sensitivity and low detection limit (0.29ng/mL), and ferritin in serum can be rapidly and accurately detected.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without inventive exercise.
FIG. 1 is a TEM image of rhodium nanoparticles prepared in example 1 of the present invention;
FIG. 2 is a diagram showing the results of pH value optimization in the rhodium nanoparticle-ferritin polyclonal antibody complex in example 2 of the present invention;
FIG. 3 is a schematic diagram showing the results of exploring and optimizing the usage amount of rhodium nanoparticles in example 2 of the present invention;
FIG. 4 is a schematic diagram showing the results of the optimization of the amount of ferritin polyclonal antibody used in example 2 of the present invention;
FIG. 5 is a graph showing the ferritin standard substance detected by the test strip prepared in example 3 of the present invention and the corresponding standard curve;
fig. 6 is a working schematic diagram of the test strip prepared in embodiment 3 of the present invention.
Detailed Description
In order to make the objects, features and advantages of the present invention more obvious and understandable, the technical solutions in the embodiments of the present invention will be clearly and completely described below, and it should be apparent that the embodiments described below are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the examples of the present invention, ferritin monoclonal antibodies (mouse anti-human ferritin monoclonal antibodies) were obtained from Wuhanyun clone science and technology GmbH, and human ferritin standards were obtained from Fitzgerald, England.
Example 1 preparation of rhodium nanoparticles
The synthesis of rhodium nanoparticles was as follows: 10mg RhCl3Dissolved in 4mL of water, 100mg of CTAC was added, followed by 1mL of 0.1M ascorbic acid, which was freshly prepared, and after stirring uniformly, the mixture was placed in an oven at 80 ℃ and reacted for 16 hours. After the reaction is finished, cooling at room temperature, 10000rpm, centrifuging for 30 minutes, taking out the precipitate, redissolving with 20mL of water, and storing the solution at normal temperature, wherein the solution is black.
The morphology of the rhodium nanoparticles prepared in this example was characterized. As shown in FIG. 1, the successful synthesis of rhodium nanoparticles with an average particle size of 48nm can be observed by a scanning electron microscope.
Example 2 preparation of rhodium nanoparticle-ferritin polyclonal antibody complexes
Preparation of ferritin polyclonal antibody:
1. animal immunization
2 New Zealand white rabbits (female) of 1.5-2kg are selected. The immunizing antigen (human ferritin) was dissolved in PBS buffer and mixed with Freund's adjuvant in equal proportion. Continuously oscillating the mixture on a vortex instrument, fully emulsifying and mixing, dropping the mixture into deionized water after 10-15min if the solution becomes paste, observing whether the liquid drops diffuse in the water, and gently oscillating the water surface, if so, continuing to emulsify, otherwise, proving that the emulsification is successful. The emulsified immunizing antigen was then immunized against New Zealand white rabbits. The experimental protocol is shown in table 1:
TABLE 1 New Zealand white rabbit immunization protocol
Figure BDA0002750993260000051
Figure BDA0002750993260000061
2. Serum preparation
After the immunization for 63 days, the rabbit anti-human ferritin polyclonal antibody is obtained by taking blood from the ear marginal vein, and the collected rabbit blood is placed at 4 ℃ overnight, so that the blood clot can be completely contracted. Centrifuging at 4 deg.C and 1000rpm for 10min, collecting supernatant, and storing at-20 deg.C for use as ferritin polyclonal antibody.
Adding K to rhodium nanoparticle solution2CO3And then adding a ferritin polyclonal antibody, reacting for 1 hour at room temperature, adding a bovine serum albumin solution for sealing the unbound sites, reacting for one hour, centrifuging and taking a precipitate to obtain the rhodium nanoparticle-ferritin polyclonal antibody compound. Dissolving a rhodium nanoparticle-ferritin polyclonal antibody compound in a redissolution, wherein the formula of the redissolution is as follows: PBS buffer containing 5% sucrose, 2% fucose, 1% PEG20000, 1% BSA and 0.25% Tween-20.
1. Exploring the pH of the coupled System
Adding 0, 2, 4, 6 and 8 mu L of 0.2M K into 1mL rhodium nanoparticle aqueous solution with the mass ratio of 1:1 and the concentration of 1.5mg/mL2CO3To change the pH of the solution, 2. mu.L of 1mg/mL anti-ferritin polyclonal antibody was then added,after reaction at room temperature for one hour, 100. mu.L of 0.1mg/mL bovine serum albumin solution was added to block unbound sites, and after reaction for one hour, the pellet was centrifuged. Dissolving the conjugate in a redissolution, wherein the formula of the redissolution is as follows: PBS buffer containing 5% sucrose, 2% fucose, 1% PEG20000, 1% BSA and 0.25% Tween-20. The conjugate was then sprayed onto a conjugate pad and observed for color development at different pH.
As shown in FIG. 2, the quality control line and the detection line have no obvious change with the increase of the pH value of the rhodium nanoparticle aqueous solution, and 0 μ L of 0.2M K is preferably added for balancing the visible signal output and the economic cost2CO3An aqueous rhodium nanoparticle solution.
2. The dosage of rhodium nano-particles is explored
Diluting 1mL of rhodium nanoparticle aqueous solution with concentration of 1.6mg/mL according to volume ratio of 1:1, 1:2, 1:4, 1:8 and 1:16, respectively adding 2 μ L of 0.2M K2CO3To change the pH of the solution, 2. mu.L of 1mg/mL anti-ferritin polyclonal antibody was added, the reaction was allowed to proceed for one hour at room temperature, and then 100. mu.L of 0.1mg/mL bovine serum albumin solution was added to block unbound sites. After one hour of reaction, the precipitate was centrifuged. Dissolving the conjugate in a redissolution, wherein the formula of the redissolution is as follows: PBS buffer containing 5% sucrose, 2% fucose, 1% PEG20000, 1% BSA and 0.25% Tween-20. The conjugate was then sprayed onto a conjugate pad and the color development of different concentrations of rhodium nanoparticle solution was observed.
As shown in fig. 3, the intensity of the quality control line and the detection line gradually decreased as the amount of rhodium nanoparticles decreased. To balance the visible signal output and economic cost considerations, a 1:2 dilution ratio of rhodium nanoparticles.
3. Explore the dosage of the ferritin polyclonal antibody
Rhodium nanoparticle aqueous solution (1.6mg/mL) was added to each of the solutions at a dilution ratio of 1: 21 mL, and each of the solutions was 2. mu. L0.2M K2CO3To change the pH of the solution, 1, 5, 10, 15, 20, 25. mu.L of 1mg/mL ferritin polyclonal antibody was added, reacted at room temperature for one hour, and then 100. mu.L of 0.1mg/mL bovine serum albumin solution was added for blocking unbound sites.After one hour of reaction, the precipitate was centrifuged. Dissolving the conjugate in a redissolution, wherein the formula of the redissolution is as follows: PBS buffer containing 5% sucrose, 2% fucose, 1% PEG20000, 1% BSA and 0.25% Tween-20. The conjugate was then sprayed onto a conjugate pad and the development of different concentrations of the anti-ferritin polyclonal antibody was observed.
As shown in FIG. 4, in the range of 1-10. mu.L of 1mg/mL ferritin polyclonal antibody, the color intensity of the detection line increased and the color intensity of the quality control line decreased with the increase of the content of the ferritin polyclonal antibody. In a typical double antibody sandwich, the more antibodies, the better the exposure and recognition of Fab and the better the recognition of antigen or target, while the control line recognizes mainly the Fc of the antibody. By adding the anti-ferritin polyclonal antibody in the range of 10-15. mu.L, the intensity of the detection line and the quality control line were almost the same, while the color intensity of the T line and the C line decreased at 20. mu.L. In view of economic cost and sensitivity, 10. mu.L is preferred as the optimum amount of the anti-ferritin polyclonal antibody.
Example 3 preparation of test strips
And the ferritin monoclonal antibody and the goat anti-rabbit antibody which are drawn on the NC membrane in a sample loading amount of 1 mu L/cm are respectively used as a detection line and a quality control line, and the rhodium nanoparticle-anti-ferritin polyclonal antibody compound is sprayed on the combination pad. The NC film is pasted on the bottom plate, the water absorption pad (one end close to the quality control line) is pasted above the bottom plate, and the combination pad and the sample pad are pasted below the bottom plate. Wherein, the interval between matter accuse line and detection line is 5mm, stacks each other with 1 mm's distance between the pad and the pad, pad and the bottom plate. Drying at 37 ℃ to obtain the test strip.
1. Optimization of the streaking concentration of antibodies on a detection line
0.1-1.0mg/mL ferritin monoclonal antibody and 1.0mg/mL goat anti-rabbit antibody are respectively drawn on an NC membrane by a sample loading amount of 1 muL/cm as a detection line and a quality control line, and simultaneously, a rhodium nanoparticle-ferritin polyclonal antibody compound of 20mg/mL is jet-printed on a binding pad by a sample loading amount of 7.5 muL/cm. The NC film is pasted on the bottom plate, the water absorption pad (one end close to the quality control line) is pasted on the bottom plate, and the combination pad and the sample pad are pasted below the bottom plate. Wherein, the interval between matter accuse line and detection line is 5mm, stacks each other with 1 mm's distance between the pad and the pad, pad and the bottom plate. After drying at 37 ℃, 100. mu.L of 2. mu.g/mL ferritin was added to observe color development.
The results showed that the detection line was darker as the concentration of ferritin monoclonal antibody loaded on the detection line increased at 0.1-0.2mg/mL, but there was no significant difference in the detection line at a gradient of 0.2-1mg/mL, at which time ferritin-binding antibody on the detection line had already been saturated, so the streaking concentration of the detection line with 0.2mg/mL antibody was preferred.
2. Streaking concentration optimization of antibodies on quality control line
0.2mg/mL of anti-ferritin monoclonal antibody and 0.1-1.0mg/mL of goat anti-rabbit antibody are respectively drawn on an NC membrane by a sample loading amount of 1 mu L/cm as a detection line and a quality control line, and meanwhile, a rhodium nanoparticle-anti-ferritin polyclonal antibody compound is jet-printed on a binding pad by a sample loading amount of 7.5 mu L/cm. The NC film is pasted on the bottom plate, the water absorption pad (one end close to the quality control line) is pasted on the bottom plate, and the combination pad and the sample pad are pasted below the bottom plate. Wherein, the interval between matter accuse line and detection line is 5mm, stacks each other with 1 mm's distance between the pad and the pad, pad and the bottom plate. After drying at 37 ℃, 100. mu.L of 2. mu.g/mL ferritin was added to observe color development.
The results show that at 0.1-1.0mg/mL, the color of the quality control line is darker as the concentration of goat anti-rabbit antibody loaded on the quality control line is increased, and at the same time, no significant difference in the color of the quality control line can be observed at the concentration of 0.2-1.0 mg/mL. Therefore, 0.2mg/mL of antibody is preferred as the streaked concentration of the control line.
3. Metal spray dosage optimization
Respectively drawing 0.2mg/mL ferritin monoclonal antibody and 0.1mg/mL goat anti-rabbit antibody on an NC membrane by using a sample loading amount of 1 mu L/cm as a detection line and a quality control line, and simultaneously spraying and printing a rhodium nanoparticle-anti-ferritin polyclonal antibody compound on a binding pad by using a sample loading amount of 7.5-10.0 mu L/cm. The NC film is pasted on the bottom plate, the water absorption pad (one end close to the quality control line) is pasted on the bottom plate, and the combination pad and the sample pad are pasted below the bottom plate. Wherein, the interval between matter accuse line and detection line is 5mm, stacks each other with 1 mm's distance between the pad and the pad, pad and the bottom plate. After drying at 37 ℃, ferritin was added at 2. mu.g/mL to observe color development.
The results showed that the color of the detection line was darker with the increase of the sprayed amount at 7.5 to 8.5. mu.L/cm, but there was no significant difference in the detection line at the gradient of 8.5 to 10.0. mu.L/cm, and it was found that the rhodium nanoparticle-ferritin polyclonal antibody complex could form a visually recognizable signal with the antibody on the detection line at the sample loading amount of 8.5. mu.L/cm, and therefore, the sample loading amount of 8.5. mu.L/cm was preferable.
4. Testing of the Standard sample
And respectively drawing 0.2mg/mL ferritin monoclonal antibody and 0.2mg/mL goat anti-rabbit antibody on an NC membrane by using a sample loading amount of 1 mu L/cm as a detection line and a quality control line, and simultaneously spraying and printing a rhodium nanoparticle-anti-ferritin polyclonal antibody compound on a binding pad by using a sample loading amount of 8.5 mu L/cm. The NC film is pasted on the bottom plate, the water absorption pad (one end close to the quality control line) is pasted on the bottom plate, and the combination pad and the sample pad are pasted below the bottom plate. Wherein, the interval between matter accuse line and detection line is 5mm, stacks each other with 1 mm's distance between the pad and the pad, pad and the bottom plate. After drying at 37 ℃, adding 100 mu L of human ferritin standard solutions (0, 1, 10, 100 and 500ng/mL) with different concentrations, observing by naked eyes after 15 minutes, and shooting images by a smart phone for gray scale calculation. And establishing a four-parameter fitting curve by taking the protein content as an abscissa and the gray value as an ordinate.
At ferritin concentrations above 50ng/mL, saturation of the developed intensity was observed based on the rhodium nanoparticle immunochromatographic strip, the lowest visually detectable amount was 1ng/mL, the difference in developed intensity was plotted as the Y-axis and ferritin concentration was plotted as the X-axis, and fitted using a four-parameter logistic equation defined below, Y ═ (a-D)/[1+ (X/C) B]+ D where a is the response at high asymptote, B is the slope factor, C is the concentration corresponding to 50% specific binding (IC50), D is the response at low asymptote, X is the calibration concentration. The four-parameter logarithmic equation is-27459.93/[ 1+ (x/4265.75) ^0.58]+26699.75，R2＝0.999。
After 15 minutes, 2 μ L of a mixed solution of 0.1M TMB solution and 0.1M hydrogen peroxide solution (molar ratio of 1: 1) was dropped on the detection line, and an image was photographed with a smartphone to perform gray scale calculation. And establishing a four-parameter fitting curve by taking the protein content as an abscissa and the gray value as an ordinate.
As shown in fig. 5, the rhodium nanoparticles can catalyze TMB to oxidized TMB, and the solution turns blue, demonstrating that the rhodium nanoparticles have enzyme-like activity. The blue color of the oxidized TMB was superimposed with the color of the rhodium nanoparticles, thereby amplifying the detection signal of ferritin. In addition, ferritin was fitted with a linear relationship between ferritin concentration and color intensity after signal enhancement at 0.01-5ng/mL with the equations of y 711.41x +2367.90 and R2 0.973, while the linear fit equation for the pre-catalytic immunochromatographic strip at 0.1-10ng/mL was y 2173.298x +2459.02 and R2 0.917. The sensitivity before and after catalysis is improved by 1.3 times through comparison.
The above-mentioned embodiments are only used for illustrating the technical solutions of the present invention, and not for limiting the same; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.

Claims (10)

1. A rhodium nanoparticle-ferritin polyclonal antibody complex comprising: rhodium nanoparticles and ferritin polyclonal antibodies coupled to the rhodium nanoparticles.
2. The rhodium nanoparticle-ferritin polyclonal antibody complex according to claim 1, wherein the mass ratio of rhodium nanoparticle to ferritin polyclonal antibody is 800: (5-25).
3. A preparation method of a rhodium nanoparticle-ferritin polyclonal antibody compound is characterized by comprising the following steps:
step 1: will be provided withRhCl3Mixing the aqueous solution, hexadecyl trimethyl ammonium chloride and ascorbic acid, and reacting to obtain rhodium nanoparticles;
step 2: and mixing the aqueous solution of the rhodium nanoparticles, an alkali solution and the anti-ferritin polyclonal antibody, reacting, and then adding a confining liquid for confining to obtain the rhodium nanoparticle-ferritin polyclonal antibody compound.
4. The method according to claim 3, wherein the concentration of the aqueous rhodium nanoparticle solution is 1.5 to 1.6mg/mL, the concentration of the alkali solution is 0.2M, the concentration of the ferritin polyclonal antibody is 1mg/mL, the concentration of the blocking solution is 0.1mg/mL, and the concentration of the aqueous rhodium nanoparticle solution is 1.5 to 1.6 mg/mL;
the volume ratio of the aqueous solution of the rhodium nanoparticles, the alkali solution, the ferritin polyclonal antibody and the blocking solution is (1000-4000): (0-8): (1-10): 100.
5. use of the rhodium nanoparticle-ferritin polyclonal antibody complex according to claim 1 or 2 or the rhodium nanoparticle-ferritin polyclonal antibody complex prepared by the preparation method according to claim 3 or 4 in ferritin detection.
6. A ferritin rapid detection test strip is characterized by comprising: a base plate;
the bottom plate is sequentially provided with a sample pad, a combination pad, a nitrocellulose membrane and absorbent paper;
the combination pad is coated with the rhodium nanoparticle-ferritin polyclonal antibody compound of claim 1 or 2 or the rhodium nanoparticle-ferritin polyclonal antibody compound prepared by the preparation method of claim 3 or 4, and the detection line of the ferritin monoclonal antibody and the quality control line of the goat anti-rabbit IgG antibody are scribed on the nitrocellulose membrane in sequence.
7. The ferritin rapid detection test strip according to claim 6 wherein the concentration of rhodium nanoparticle-ferritin polyclonal antibody complex is 5-30mg/mL and the spray dose is 7.5-10.0 μ L/cm;
the concentration of the ferritin monoclonal antibody is 0.1-1.0mg/mL, and the spraying amount is 1 muL/cm;
the concentration of the goat anti-rabbit IgG antibody is 0.1-1.0mg/mL, and the spraying amount is 1 muL/cm.
8. The ferritin rapid detection test strip of claim 6 further comprising: a mixed solution of a 3,3',5,5' -tetramethylbenzidine solution and a hydrogen peroxide solution.
9. A method for rapidly detecting ferritin in serum is characterized by comprising the following steps:
dropping the serum to be detected on the sample pad in the test strip for rapid detection of ferritin according to claim 6, wherein if the detection line and the quality control line both develop color, the serum to be detected contains ferritin, and if the detection line does not develop color and the quality control line develops color, the serum to be detected does not contain ferritin.
10. The method for rapidly detecting ferritin in serum according to claim 9 wherein the amount of serum to be detected is 80-150 μ L.
CN202011184144.9A 2020-10-29 2020-10-29 Rhodium nanoparticle-ferritin polyclonal antibody compound and ferritin rapid detection test strip Pending CN112379102A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011184144.9A CN112379102A (en) 2020-10-29 2020-10-29 Rhodium nanoparticle-ferritin polyclonal antibody compound and ferritin rapid detection test strip

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011184144.9A CN112379102A (en) 2020-10-29 2020-10-29 Rhodium nanoparticle-ferritin polyclonal antibody compound and ferritin rapid detection test strip

Publications (1)

Publication Number Publication Date
CN112379102A true CN112379102A (en) 2021-02-19

Family

ID=74577491

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011184144.9A Pending CN112379102A (en) 2020-10-29 2020-10-29 Rhodium nanoparticle-ferritin polyclonal antibody compound and ferritin rapid detection test strip

Country Status (1)

Country Link
CN (1) CN112379102A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106405109A (en) * 2016-09-06 2017-02-15 北京华科泰生物技术有限公司 Activated fluorescent latex microsphere used for ferritin fluorescence immunoassay chromatography detection card
CN107290540A (en) * 2017-06-22 2017-10-24 中国农业大学 Escherichia coli O 157:H7 and the common Test paper of salmonella typhimurium and preparation method and application
WO2020016571A1 (en) * 2018-07-16 2020-01-23 Donnelly George Arthur Ferritin analysis via lateral flow immunoassay

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106405109A (en) * 2016-09-06 2017-02-15 北京华科泰生物技术有限公司 Activated fluorescent latex microsphere used for ferritin fluorescence immunoassay chromatography detection card
CN107290540A (en) * 2017-06-22 2017-10-24 中国农业大学 Escherichia coli O 157:H7 and the common Test paper of salmonella typhimurium and preparation method and application
WO2020016571A1 (en) * 2018-07-16 2020-01-23 Donnelly George Arthur Ferritin analysis via lateral flow immunoassay

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKRAM VALIPOUR ET AL.: "TiO2 nanoparticles doped with Celestine Blue as a label in a sandwich immunoassay for the hepatitis C virus core antigen using a screen printed electrode", 《MICROCHIM ACTA》 *
TATIANA G. CHOLEVA ET AL.: "Intrinsic peroxidase-like activity of rhodium nanoparticles,and their application to the colorimetric determination of hydrogen peroxide and glucose", 《MICROCHIMICA ACTA》 *
WEI YE ET AL.: "Kinetics-controlled growth of bimetallic RhAg on Au nanorods and their catalytic properties", 《NANOSCALE》 *
YAN GUO ET AL.: "Pore structure dependent activity and durability of mesoporous rhodium nanoparticles towards the methanol oxidation reaction", 《CHEMICAL COMMUNICATIONS》 *

Similar Documents

Publication Publication Date Title
WO2019148754A1 (en) Test strip and testing method for pla2r antibody
CA1292181C (en) Use of polyoxyethylene ethers to improve the performance of immunoassays employing peroxidase conjugates
WO2019148753A1 (en) Test strip and testing method for thsd7a antibody
CN108226466B (en) Immunochromatographic test strip and immunochromatographic detection method
CN103201057A (en) Blue-colored gold nanoparticles for immunological measurement, process for production of same, and measurement method using same
CN106053794A (en) Reagent card for accurately detecting test object, kit and application
CN105866417A (en) Immunochromatography test strip based on combination of super paramagnetic ferric oxide nano-particle aggregate and Prussian blue dyeing and preparing method and application of immunochromatography test strip
CN109212192A (en) GP73 detection kit for primary carcinoma of liver early diagnosis
CN115267194A (en) Indirect competitive enzyme-linked immunosorbent assay method for detecting aflatoxin B1
CN105606597B (en) A kind of Chemoluminescent substrate and utilize its Procalcitonin detection kit
CN112379102A (en) Rhodium nanoparticle-ferritin polyclonal antibody compound and ferritin rapid detection test strip
CN104897889B (en) Fluorescence SiO2The preparation method of colloidal agent and use fluorescence SiO2The reagent paper of colloidal agent
CN115792218A (en) Manganese dioxide nanosheet-mediated vomitoxin detection kit and detection method
CN116840460A (en) Lateral flow immunoassay kit and method for detecting aflatoxin B1
CN116298261A (en) Preparation method and application of kit for quantitatively detecting D-dimer
US3957435A (en) Passive hemagglutination test method and composition for use therein
CN109776563B (en) Vomitoxin hapten, preparation method thereof, artificial antigen, kit and vomitoxin detection method
CN109187943B (en) Anti-interference reagent cup and preparation method of anti-interference coating in reagent cup
JPS61280568A (en) Method for measuring components in bodily fluids
EP0834741A1 (en) Colloidal gold immunoassay method
CN112710842A (en) HsCRP detection kit and detection method of hsCRP
CN109655626A (en) A kind of detection kit and its method of complete homogeneous determination glucagon
CN115980343B (en) Chemiluminescent lateral flow immunoassay method
CN220357087U (en) C-reactive protein immunochromatography detection reagent detection card
CN108148130A (en) A kind of application of the preparation method and NOTA of heavy metal Hg artificial antigen in heavy metal Hg artificial antigen reagent is prepared

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210219

RJ01 Rejection of invention patent application after publication